Recent News

• 09.05.2025 - Optimizing Cell Viability in a GMP Workflow
• 09.05.2025 - 10 Reasons to Use Dry Thawing in Cell Therapy Processes
• 08.05.2025 - Azenta Reports Third Quarter Results for Fiscal 2025, Ended June 30, 2025; Reiterates Full Year Fiscal 2025 Guidance
• 07.31.2025 - Azenta Life Sciences Partners with Frenova, a Division of Fresenius Medical Care, and Nephronomics to Advance Genomic Research in Nephrology
• 07.30.2025 - Azenta to Participate in 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
• 07.23.2025 - Azenta Announces Fiscal 2025 Third Quarter Earnings Conference Call and Webcast
• 06.30.2025 - Revolutionize Frozen Sample Handling and Tracking with Radio-Frequency Tagging
• 06.23.2025 - 5 Ways Optimized Cell Line Management Helps Streamline Cell Therapy Workflows

Recent Filings

• 08.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.05.2025 - 8-K Current report
• 08.05.2025 - EX-99.1 EX-99.1
• 07.18.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.02.2025 - 8-K Current report
• 06.04.2025 - 4/A Statement of changes in beneficial ownership of securities
• 06.04.2025 - 4 Statement of changes in beneficial ownership of securities